Newcastle disease virus (NDV), an avian paramyxovirus, enters the host cell by fusion of viral and host cell membranes. The fusion of two membranes is mediated by the viral fusion (F) protein. The F protein, like other class I fusion proteins, is thought to undergo major conformational changes during the fusion process. The exact mechanism that leads to major refolding of F protein is not clear. Recently, it has been proposed that disulfide bond reduction in the fusion protein of some viruses may be involved in the conformational changes in fusion proteins. In some viruses, the reduction of disulfide bonds in the fusion protein is mediated by host cell disulfide isomerases belonging to the protein disulfide isomerase (PDI) family. In this study, the role of disulfide bond isomerization in the entry of NDV was analyzed. Using inhibitors of thiol-disulfide isomerases, we found that blocking the reduction of disulfide bonds in the fusion protein inhibited cell-cell fusion as well as virus entry into the host cell. Also, over-expression of isomerases belonging to the PDI family significantly enhanced cell-cell fusion. Taken together, these results suggest that free thiols play an important role in fusion mediated by NDV glycoproteins. Using a thiol specific, membrane impermeable biotin, MPB, we found that free thiols are produced in cell surface-expressed NDV F protein. The production of free thiols was inhibited by inhibitors of thiol-disulfide isomerases. Over-expression of isomerases belonging to the PDI family enhanced detection of free thiols in F protein. In F protein, present in virions or in virus-like particles, free thiols were detected only after the particles were attached to target cells. Taken together, these results suggest that free thiols are produced in F protein and the production of free thiols is mediated by host cell thiol-disulfide isomerases. Using conformation sensitive antibodies, we also studied the conformation of cell surface-expressed F protein in the presence ofthiol-disulfide isomerase inhibitors or in cells over-expressing thiol-disulfide isomerases. In the presence of thiol-disulfide isomerase inhibitors, the cell surface-expressed F protein was in a prefusion conformation while in cells over-expressing thiol-disulfide isomerases the F protein was in a post-fusion conformation. We also correlated the production of free thiols to the conformational changes in F protein. Using temperature-arrested intermediates or F protein with mutations in heptad repeat domains, which are defective in attaining intermediate conformations, we found that free thiols are produced before any of the proposed conformational changes in F protein. Also, the production of free thiols in F protein was found to be independent of its activation by hemagglutinin-neuraminidase (HN) protein. These results suggest that free thiols are probably required for the activation of F protein during membrane fusion.

The final step of paramyxovirus infection requires the assembly of viral structural components at the plasma membrane of infected cells followed by budding of virions. While the matrix (M) protein of some paramyxoviruses has been suggested to play a central role in the assembly and release of virus particles, the specific viral and host protein requirements are still unclear. Using Newcastle disease virus (NDV) as a prototype paramyxovirus, we explored the role of each of the NDV structural proteins in virion assembly and release. For these studies, we established a virus-like particle (VLP) system for NDV. The key viral proteins required for particle formation and the specific viral protein-protein interactions required for assembly and release of particles were explored in chapter 2. First we found that co-expression of all four proteins resulted in the release of VLPs with densities and efficiencies of release (1.18 to 1.16 g/cm3and 83.8%±1.1, respectively) similar to that of authentic virions. Expression of M protein alone, but not NP, F-K115Q or HN proteins individually, resulted in efficient VLP release. No combination of proteins in the absence of M protein resulted in particle release. Expression of any combination of proteins that included M protein yielded VLPs, although with different densities and efficiencies of release. To address the roles of NP, F and HN proteins in VLP assembly, the interactions of proteins in VLPs formed with different combinations of viral proteins were characterized by co-immunoprecipitation. The co-localization of M protein with cell surface F and HN proteins in cells expressing all combinations of viral proteins was characterized. Taken together, the results show that M protein is necessary and sufficient for NDV budding. Furthermore, they suggest that M protein – HN protein and M protein - NP interactions are responsible for incorporation of HN protein and NP proteins into VLPs and that F protein is incorporated indirectly due to interactions with NP and HN protein. Since the vacuolar protein sorting (VPS) system is involved in the release of several enveloped RNA viruses, chapter 3 describes studies which explored the role of the VPS system on NDV particle release. First, we characterized the effects of three dominant negative mutant proteins of the VPS pathway on particle release. Expression of dominant negative mutants of CHMP3, Vps4 and AIP1 proteins inhibited M protein particle release as well as release of complete VLPs. Mutation of a YANL sequence in the NDV M protein to AANA inhibited particle release while replacement of this sequence with either of the classical late domain motifs, PTAP or YPDL, completely restored particle release. The host protein AIP1, which binds YXXL late domain sequences, is incorporated into M protein particles. These results suggest that an intact VPS pathway is necessary for NDV VLP release and that the YANL sequence is an NDV M protein L domain. The sequence and structure of the Newcastle disease virus (NDV) fusion (F) protein are consistent with its classification as a type 1 glycoprotein. We have previously reported, however, that F protein can be detected in at least two topological forms with respect to membranes in both a cell-free protein synthesizing system containing membranes as well as infected COS-7 cells (J. Virol. 2004 77:1951). One form is the classical type 1 glycoprotein while the other is a polytopic form in which approximately 200 amino acids of the amino terminal end as well as the cytoplasmic domain (CT) are translocated across membranes. Furthermore, we detected CT sequences on surfaces of F protein expressing cells and antibodies specific for these sequences inhibited red blood cell fusion to HN and F protein expressing cells suggesting a role for surface expressed CT sequences in cell-cell fusion. In chapter 4, we extended these findings and found that the alternate form of the F protein can also be detected in infected and transfected avian cells, the natural host cells of NDV. Furthermore, the alternate form of F protein was also found in virions released from both infected COS-7 cells and avian cells by Western analysis. Mass spectrometry confirmed its presence in virions released from avian cells. Two different polyclonal antibodies raised against sequences of the CT domain of the F protein slowed plaque formation in both avian and COS-7 cells. Antibody specific for the CT domain also inhibited single cycle infections as detected by immunofluorescence of viral proteins in infected cells. The potential roles of this alternate form of the NDV F protein in infection are discussed. Virus-like particles (VLPs) generated from different viruses have been shown to have potential as good vaccines. Chapter 5 explored the potential of NDV VLPs as a vaccine for NDV or as a vaccine vector for human pathogens. Significant quantities of NDV VLPs can be produced from tissue culture cells. These VLPs are as pure as virions prepared in eggs. In addition, some rules for incorporation of viral proteins into VLPs were also explored. We found that the cytoplasmic domain of the fusion (F) protein is necessary for its incorporation into VLPs. We found that an HN protein with an HA tag at its carboxyl terminus was incorporated into VLPs. We also found that the HN and F proteins of NDV, strain B1, can be incorporated into VLPs with M and NP of strain AV. The demonstration of specific domains required for protein incorporation into particles is important in using NDV VLPs as a vaccine vector for important human pathogens. In conclusion, this dissertation presents results that show that the M protein plays a central role in NDV assembly and release, a finding that is consistent with findings with other paramyxoviruses. More importantly, this work extends the current knowledge of paramyxovirus assembly and release by providing the first direct evidence of interactions between paramyxovirus proteins. These interactions between viral proteins provide a rational basis for incorporation of viral proteins into particles. This work also provides a clearer understanding of the role of the host vacuolar protein sorting machinery in NDV budding. A clear understanding of virus assembly and budding process contributes to the design of strategies for therapeutic intervention and in the development of safer, more economical and effective vaccines.

The societal burden of autoimmune diseases and donor organ transplant rejection in developed countries reflects the lack of effective immune suppressive drugs. The main objective of my thesis was to develop novel fusion proteins targeting receptors linked to autoimmunity; strategies that will allow the suppression of autoreactive cells while sparing resting lymphocytes. Interleukin (IL) 15 has been demonstrated to exert its effects mainly on activated T-cells triggered via their T-cell receptor (TCR). Since we found that the fusion of granulocyte-macrophage colony stimulating factor (GMCSF) to IL15 - aka GIFT15 - paradoxically leads to aberrant signalling downstream of the IL15R and blocks interferon (IFN)-gamma secretion in a mixed lymphocyte reaction (MLR), we hypothesized to use this fusokine in proof-of-principle cell transplantation models and shown that GIFT15 can indeed block the rejection of allogeneic and xenogeneic cells in immunocompetent mice. Additionally, we found that ex vivo GIFT15 treatment of mouse splenocytes lead to the generation of regulatory B-cells (Bregs). These Bregs express high levels of MHCII, IL10 and are capable to block antigen (Ag)-presentation in vitro as third party bystander cells. Moreover, a single injection of these GIFT15-generated Bregs in mice with pre-developed experimental autoimmune encephalomyelitis (EAE) leads to long lasting remission of disease. / Along those lines, we also found that mesenchymal stromal cells (MSCs) lead to the paracrine conversion of CCL2 to an antagonist form capable of specifically inhibiting plasma cells and activated Th17 cells. This mechanistic insight informed the design of a second class of suppression fusokine. Namely, the fusing of antagonist CCL2 to GMCSF - aka GMME1. We tested its potential use in autoimmune diseases such as EAE and rheumatoid arthritis (RA). We demonstrated that GMME1 leads to asymmetrical signalling and inhibition of plasma cells as well as Th17 EAE/RA-reactive CD4 T-cells. The net outcome of these pharmacological effects is the selective depletion of CCR2-reactive T-cells as demonstrated both in vitro and in vivo. / Overall, our data support the use of our fusion proteins as part of a powerful and specific immunosuppressive strategy either as directly injectable protein biopharmaceuticals or through the ex vivo generation of autologous Bregs in the case of GIFT15.

Dissertation (Ph.D.)--University of South Florida, 2009. / Includes vita. Includes bibliographical references. Also available online.

Dissertation (Ph.D.)--University of South Florida, 2009. / Title from PDF of title page. Document formatted into pages; contains 149 pages. Includes vita. Includes bibliographical references.

The human Philadelphia chromosome (Ph) arises from a translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)]. The resulting chimeric BCR-ABLoncogene encodes a constitutively activated, oncogenic tyrosine kinase that induces chronic myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL). The BCR-ABL tyrosine kinase inhibitor (TKI), imatinib mesylate, induces a complete hematologic and cytogenetic response in the majority of CML patients, but is unable to completely eradicate BCR-ABL–expressing leukemic cells, suggesting that leukemia stem cells are not eliminated. Over time, patients frequently become drug resistant and develop progressive disease despite continued treatment. Two major reasons cause the imatinib resistance. The first one is the BCR-ABL kinase domain mutations which inhibit the interaction of BCR-ABL kinase domain with imatinib; the second one is the residual leukemia stem cells (LSCs) in the patients who are administrated with imatinib. To overcome these two major obstacles in CML treatment, new strategies need further investigation. As detailed in Chapter II, we evaluated the therapeutic effect of Hsp90 inhibition by using a novel water-soluble Hsp90 inhibitor, IPI-504, in our BCR-ABL retroviral transplantation mouse model. We found that BCR-ABL mutants relied more on the HSP90 function than WT BCR-ABL in CML. More interestingly, inhibition of HSP90 in CML leukemia stem cells with IPI-504 significantly decreases the survival and proliferation of CML leukemia stem cells in vitro and in vivo. Consistent with these findings, IPI-504 treatment achieved significant prolonged survival of CML and B-ALL mice. IPI-504 represents a novel therapeutic approach whereby inhibition of Hsp90 in CML patients and Ph+ ALL may significantly advance efforts to develop a cure for these diseases. The rationale underlying the use of IPI-504 for kinase inhibitor–resistant CML has implications for other cancers that display oncogene addiction to kinases that are Hsp90 client proteins. Although we proved that inhibition of Hsp90 could restrain LSCs in vitro and in vivo, it is still unclear how to define specific targets in LSCs and eradicate LSCs. In Chapter III, we took advantage of our CML mouse model and compared the global gene expression signature between normal HSCs and LSCs to identify the downregulation of Pten in CML LSCs. CML develops faster when Pten is deleted in Ptenfl/fl mice. On the other hand, Pten overexpression significantly delays the CML development and impairs leukemia stem cell function. mTOR is a major downstream of Pten-Akt pathway and it is always activated or overepxressed when Pten is mutated or deleted in human cancers. In our study, we found that inhibition of mTOR by rapamycin inhibited proliferation and induced apoptosis of LSCs. Notably, our study also confirmed a recent clinical report that Pten has been downregulated in human CML patient LSCs. In summary, our results proved the tumor suppressor role of Pten in CML mouse model. Although the mechanisms of Pten in leukemia stem cells still need further study, Pten and its downstream, such as Akt and mTOR, should be more attractive in LSCs study.

No description available.

No description available.

Styrol-Monooxygenasen (SMOs) spielen im bakteriellen Abbau von Styrol eine wichtige Rolle. Sie epoxidieren den Kohlenwasserstoff zu (S)-Styroloxid und waren bis vor kurzem vor allem aus Gram-negativen Vertretern wie Pseudomonaden bekannt. Das Grampositive nocardioforme Bodenbakterium Rhodococcus opacus 1CP kann Styrol als Energie- und Kohlenstoffquelle nutzen und verfügt über zwei Typen von SMOs. Neben StyA2B, einer fusionierten FAD:NADH-Oxidoreduktase (StyB) und Monooxygenase (StyA2) findet sich eine weitere Monooxygenase StyA1, deren Gen direkt stromaufwärts zu styA2B lokalisiert ist. Zusätzlich zum natürlichen Fusionsprotein StyA2B gelang kürzlich die Konstruktion künstlicher Fusionen StyAL1B und StyAL2B aus Pseudomonas fluorescens ST. Um sowohl StyA1/StyA2B als auch die künstlichen Fusionen StyAL1B und StyAL2B für eine biotechnologische Anwendung nutzen zu können, wurde im Rahmen dieser Arbeit angestrebt, ihre spezifische Oxygenierungsaktivität (StyA1/StyA2B: 0,24 U/mg) mit Hilfe der error prone PCR zu erhöhen. Um Veränderungen der katalytischen Aktivität in einer großen Zahl von Mutanten schnell zu erkennen, ist ein einfacher Screeningtest erforderlich. Die Fähigkeit von SMOs zur Oxidation von Indol zu blauem Indigo bietet diese Möglichkeit. Allerdings ist hierfür die Expression löslicher Proteine eine wesentliche Voraussetzung. Versuche zur Veränderung der Gene styA2B und styA1A2B mit Hilfe eines kommerziellen error prone PCR Kits lieferten ca. 300 bis 1.200 mutmaßlich veränderte Klone, welche jedoch keinerlei Aktivität für den Indolumsatz zeigten. Als Ursache wurde eine Expression der Proteine in Form inaktiver Inclusion Bodies vermutet. Die Fusionsproteine StyAL1B und StyAL2B bilden lösliches Protein, welche Indol zum blauen Farbstoff Indigo umsetzen. Verschiedene Kultivierungsbedingungen wurden auf den Umsatz von Indol untersucht. Dabei wurde erkannt, dass die Klone sich nicht identisch bezüglich ihrer Proteinlöslichkeit verhalten. Mit Hilfe dieser Ergebnisse wurde ein Test für das Aktivitätsscreening von Styrol-Monooxygenasen auf Platte entwickelt. Die Erhöhung der NaCl-Konzentration im Medium steigerte die Indoloxidation, welche sich jedoch durch zusätzliche physiologisch Faktoren schwer beeinflussen lassen. Auch für die Fusionsproteine erfolgte die Durchführung einer error prone PCR. Der Schritt der error prone PCR stellte kein Problem dar, jedoch die Einbindung des veränderten Genfragmentes in den Vektor, beziehungsweise dessen Transformation in E. coli. Alternative Strategien, wie die Nutzung alternativer DNA Polymerasen und eines konventionellen Konzepts, bei dem veränderte Gene in geschnittene Expressionsvektoren ligiert werden, führte zu keinen detektierbaren Klonen. Die Kultivierung von identischen Klonen auf Festmedium wirkte sich aufgrund nicht näher identifizierter Einflüsse auf das Verhalten bezüglich der Indoloxidation sehr unterschiedlich aus. Um diese Einflüsse zu minimieren, erfolgte die Untersuchung des Systems in einer Flüssigkultur. Im Blickpunkt stand hierbei die Indigoproduktion von E. coli BL21 (pET_StyAL2B) die in Abhängigkeit der optischen Dichte der Kultur untersucht wurde. / Styrene monooxygenases (SMOs) play an important role in the bacterial degradation of styrene. They epoxidize the hydrocarbon highly enantioselective to (S)-styrene oxide. Most of the styrene monooxygenases known so far were identified in Gram-negative microorganisms like pseudomonads. Rhodococcus opacus 1CP, a Gram-positive nocardioform actinobacterium, which uses styrene as energy and carbon source was recently found to possess a novel type of SMO, StyA2B. This protein represents a natural fusion between an FAD:NADH oxidoreductase (StyB) and a single monooxygenase subunit (StyA2) and might act in combination with another single oxygenase StyA1 in strain 1CP. Two artificial analogs to StyA2B, designated StyAL1B and StyAL2B, were recently prepared by a fusion of styA and styB of Pseudomonas fluorescens ST and both showed oxygenating activity. For StyA1/StyA2B as well as the artificial fusion proteins StyAL1B and StyAL2B, it was tried to enhance the specific oxygenation activity in order to support their biotechnological applicability. The method of error prone PCR was used for that purpose. In order to identify favorable modifications with increased catalytic activity from a high number of mutants, an easy and simple screening test is necessary. Therefore, it is reasonable to use the ability of SMOs to oxidize indole to the blue dye indigo. However, the expression of SMOs as soluble proteins is an important requirement for any activity screening. Attempts to modify the genes styA2B and styA1/styA2B by means of a commercial error prone PCR kit yielded 300 to 1,200 potential mutants. Unfortunately, none of the obtained colonies showed any indole-oxidizing activity and the formation of insoluble inclusion bodies was assumed to be a likely explanation. In contrast to StyA2B and StyA1, recombinant expression of the artificial fused SMOs StyAL1B und StyAL2B should yield detectable amounts of active proteins. In fact, cultivation of clones expressing both types of proteins showed a blue coloration. Since the coloration of clones from one single solid medium evolved in a non-uniform manner, cultivation conditions were varied in order to identify factors which promote a more uniform tendency for indole oxidation. Although a high NaCl concentration in the medium was shown to favor indole oxidation, the latter one seems to be influenced by additional physiological factors, hardly to control. For the artificially fused proteins an error prone PCR was carried out, too. Although the initial step of mutagenic PCR was found to be successful, completing the vector system by a second ll-up PCR reaction failed. Alternative strategies like the usage of alternative DNA polymerases as well as a conventional cloning approach of various genes into a digested expression vector did not lead to detectable clones. The cultivation of identical clones on petri dishes provided no uniform tendency for indole oxidation and thus did not allow the reliable comparison of mutants in respect of their specific SMO activities. Cultivation of mutants in liquid medium should lead to more reproducible conditions and for that purpose a method was successfully established to quantify indigo formation and cell density.

Styrol-Monooxygenasen (SMOs) spielen im bakteriellen Abbau von Styrol eine wichtige Rolle. Sie epoxidieren den Kohlenwasserstoff zu (S)-Styroloxid und waren bis vor kurzem vor allem aus Gram-negativen Vertretern wie Pseudomonaden bekannt. Das Grampositive nocardioforme Bodenbakterium Rhodococcus opacus 1CP kann Styrol als Energie- und Kohlenstoffquelle nutzen und verfügt über zwei Typen von SMOs. Neben StyA2B, einer fusionierten FAD:NADH-Oxidoreduktase (StyB) und Monooxygenase (StyA2) findet sich eine weitere Monooxygenase StyA1, deren Gen direkt stromaufwärts zu styA2B lokalisiert ist. Zusätzlich zum natürlichen Fusionsprotein StyA2B gelang kürzlich die Konstruktion künstlicher Fusionen StyAL1B und StyAL2B aus Pseudomonas fluorescens ST. Um sowohl StyA1/StyA2B als auch die künstlichen Fusionen StyAL1B und StyAL2B für eine biotechnologische Anwendung nutzen zu können, wurde im Rahmen dieser Arbeit angestrebt, ihre spezifische Oxygenierungsaktivität (StyA1/StyA2B: 0,24 U/mg) mit Hilfe der error prone PCR zu erhöhen. Um Veränderungen der katalytischen Aktivität in einer großen Zahl von Mutanten schnell zu erkennen, ist ein einfacher Screeningtest erforderlich. Die Fähigkeit von SMOs zur Oxidation von Indol zu blauem Indigo bietet diese Möglichkeit. Allerdings ist hierfür die Expression löslicher Proteine eine wesentliche Voraussetzung. Versuche zur Veränderung der Gene styA2B und styA1A2B mit Hilfe eines kommerziellen error prone PCR Kits lieferten ca. 300 bis 1.200 mutmaßlich veränderte Klone, welche jedoch keinerlei Aktivität für den Indolumsatz zeigten. Als Ursache wurde eine Expression der Proteine in Form inaktiver Inclusion Bodies vermutet. Die Fusionsproteine StyAL1B und StyAL2B bilden lösliches Protein, welche Indol zum blauen Farbstoff Indigo umsetzen. Verschiedene Kultivierungsbedingungen wurden auf den Umsatz von Indol untersucht. Dabei wurde erkannt, dass die Klone sich nicht identisch bezüglich ihrer Proteinlöslichkeit verhalten. Mit Hilfe dieser Ergebnisse wurde ein Test für das Aktivitätsscreening von Styrol-Monooxygenasen auf Platte entwickelt. Die Erhöhung der NaCl-Konzentration im Medium steigerte die Indoloxidation, welche sich jedoch durch zusätzliche physiologisch Faktoren schwer beeinflussen lassen. Auch für die Fusionsproteine erfolgte die Durchführung einer error prone PCR. Der Schritt der error prone PCR stellte kein Problem dar, jedoch die Einbindung des veränderten Genfragmentes in den Vektor, beziehungsweise dessen Transformation in E. coli. Alternative Strategien, wie die Nutzung alternativer DNA Polymerasen und eines konventionellen Konzepts, bei dem veränderte Gene in geschnittene Expressionsvektoren ligiert werden, führte zu keinen detektierbaren Klonen. Die Kultivierung von identischen Klonen auf Festmedium wirkte sich aufgrund nicht näher identifizierter Einflüsse auf das Verhalten bezüglich der Indoloxidation sehr unterschiedlich aus. Um diese Einflüsse zu minimieren, erfolgte die Untersuchung des Systems in einer Flüssigkultur. Im Blickpunkt stand hierbei die Indigoproduktion von E. coli BL21 (pET_StyAL2B) die in Abhängigkeit der optischen Dichte der Kultur untersucht wurde.:Eidesstattliche Erklärung II Danksagung III Zusammenfassung IV Abstract VI Abbildungsverzeichnis XI Tabellenverzeichnis XIII Abkürzungsverzeichnis XIV 1 Einleitung 1 1.1 Styrol - ein Produkt der Industrie . . . . . . . . . . . . . . . . . . . . . . . 1 1.2 Styrol-Monooxygenasen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 1.2.1 Abbauwege von Styrol . . . . . . . . . . . . . . . . . . . . . . . . . 2 1.2.2 Struktur, Vorkommen und Eigenschaften klassischer Zweikomponenten Styrol-Monooxygenasen . . . . . . . . . . . . . . . . . . . . 4 1.2.3 Das neuartige Styrol-Monooxygenase-System StyA1/StyA2B aus Rhodococcus opacus 1CP . . . . . . . . . . . . . . . . . . . . . . . . 6 1.2.4 Künstlich verlinkte SMO aus Pseudomonas uorescens ST . . . . . 7 1.2.5 Biotechnologischer Einsatz von Styrol-Monooxygenasen . . . . . . . 8 1.3 Strategien des Protein-Engineering . . . . . . . . . . . . . . . . . . . . . . 9 1.3.1 Arbeitsmethoden zur Veränderung von DNA . . . . . . . . . . . . . 9 1.3.2 Error prone PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 1.4 Arbeitsziele . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 2 Material und Methoden 13 2.1 Bakterienstämme und Plasmide . . . . . . . . . . . . . . . . . . . . . . . . 13 2.2 Kultivierungsmedien und -bedingungen . . . . . . . . . . . . . . . . . . . . 14 2.2.1 Kultivierungsmedien . . . . . . . . . . . . . . . . . . . . . . . . . . 14 2.2.2 Kultivierungstemperaturen . . . . . . . . . . . . . . . . . . . . . . . 14 2.3 Polymerase-Kettenreaktion (PCR) . . . . . . . . . . . . . . . . . . . . . . 16 2.3.1 Primer und Primerdesign . . . . . . . . . . . . . . . . . . . . . . . . 16 2.3.2 Standard-PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 2.4 Fehlerbehaftete Polymerase-Kettenreaktion (epPCR) . . . . . . . . . . . . 17 2.4.1 Synthese der mutagenen Megaprimer . . . . . . . . . . . . . . . . . 18 2.4.2 EZClone Reaktion . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 2.4.3 Transformation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 2.4.4 Modi zierung des Protokolls des EZClone Reaktion Schrittes . . . . 20 2.5 Aufreinigung von PCR-Produkten aus der Lösung . . . . . . . . . . . . . . 20 2.6 TAE-Agarose-Gelelektrophorese . . . . . . . . . . . . . . . . . . . . . . . . 20 2.7 DNA-Extraktion aus Agarosegelen . . . . . . . . . . . . . . . . . . . . . . 21 2.8 Bestimmung der DNA-Konzentration . . . . . . . . . . . . . . . . . . . . . 21 2.9 Restriktionsverdau von DNA . . . . . . . . . . . . . . . . . . . . . . . . . . 21 2.10 Ligation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 2.11 Herstellung von kompetenten Zellen (E.coli DH5ff, E. coli BL21) . . . . . 23 2.11.1 Chemisch kompetente Zellen nach der CaCl2-Methode (42) . . . . . 23 2.11.2 TOP10 chemischkompetente Zellen . . . . . . . . . . . . . . . . . . 23 2.12 Transformation nach der Hitzeschock-Methode (19) . . . . . . . . . . . . . 24 2.13 Plasmidpräparation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 2.14 Bestimmung der Indigobildung durch Klone mit mutmaÿlicher SMO-Aktivität 24 2.14.1 Abschätzung der Indigobildung durch Augenschein . . . . . . . . . 25 2.14.2 Quanti zierung der Indigobildung mittels UV/Vis-Spektrophotometrie 25 2.14.3 Quanti zierung der Indigobildung aus Flüssigkulturen . . . . . . . . 26 3 Ergebnisse 27 3.1 Versuche der error prone PCR von StyA2B aus Rhodococcus opacus 1CP . 27 3.1.1 Isolation von Templat-DNA und Durchführung der error prone PCR 28 3.1.2 Screening von Transformanden auf Fähigkeit zur Indol-Oxidation . 29 3.1.3 Herstellung und Aktivitätsscreening von E. coli DH5ff pET_StyA2B 30 3.2 Versuche der error prone PCR von styA1/styA2B aus Rhodococcus opacus 1CP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 3.2.1 Durchführung der error prone PCR und Aktivitätsscreening von StyA1/StyA2B in pBluescript KS(+) . . . . . . . . . . . . . . . . . 31 3.2.2 Durchführung des Aktivitätsscreening von StyA1/StyA2B in pET16bP 32 3.3 Fusionsproteine StyAL1B und StyAL2B aus Pseudomonas uorescens ST . 33 3.3.1 Optimierung der Zusammensetzung des LB-Mediums für das Aktivitätsscreenings von pET_StyAL2B in E. coli BL21 nach einer Transformation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 3.3.2 Ein uss der Belüftung auf die Neigung von E. coli BL21 (pET_StyAL2B) Kolonien zur Oxidation von Indol . . . . . . . . . . . . . . . . . . . 38 3.3.3 Bestimmung der Indigobildung mittels UV/Vis-Spektroskopie . . . 40 3.3.4 Zeitliche Entwicklung der Indigokonzentration einer Flüssigkultur von E. coli BL21 (pET_StyAL2B) . . . . . . . . . . . . . . . . . . 42 3.3.5 Error prone PCR von pET_StyAL2B mit Gene Morph II EZ Clone Kit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 3.3.6 Error prone PCR nach der klassischen Methode mit pET_StyAL1B und pET_StyAL2B . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 4 Diskussion der Ergebnisse 49 4.1 Die error prone PCR als attraktive Methodik zur Optimierung von Styrol- Monooxygenasen hinsichtlich katalytischer Eigenschaften . . . . . . . . . . 49 4.2 Der Aktivitätsnachweis als mutmaÿlich limitierender Schritt in der Modi- zierung von StyA2B und StyA1/StyA2B mit Hilfe der error prone PCR . 51 4.3 Die künstlich fusionierten Styrol-Monooxygenasen StyAL2B und StyAL1B erlauben ein Aktivitätsscreening auf Platte . . . . . . . . . . . . . . . . . . 53 4.4 Die Entwicklung einer Methodik zur Quanti zierung der spezi schen Indigobildung eines Expressionsklons der Styrol-Monooxygenase StyAL2B . . . 58 4.5 Fehleranalyse zur error prone PCR . . . . . . . . . . . . . . . . . . . . . . 59 4.5.1 Fehler in der klassischen error prone PCR für pET_StyAL1B und pET_StyAL2B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 Literaturverzeichnis 65 / Styrene monooxygenases (SMOs) play an important role in the bacterial degradation of styrene. They epoxidize the hydrocarbon highly enantioselective to (S)-styrene oxide. Most of the styrene monooxygenases known so far were identified in Gram-negative microorganisms like pseudomonads. Rhodococcus opacus 1CP, a Gram-positive nocardioform actinobacterium, which uses styrene as energy and carbon source was recently found to possess a novel type of SMO, StyA2B. This protein represents a natural fusion between an FAD:NADH oxidoreductase (StyB) and a single monooxygenase subunit (StyA2) and might act in combination with another single oxygenase StyA1 in strain 1CP. Two artificial analogs to StyA2B, designated StyAL1B and StyAL2B, were recently prepared by a fusion of styA and styB of Pseudomonas fluorescens ST and both showed oxygenating activity. For StyA1/StyA2B as well as the artificial fusion proteins StyAL1B and StyAL2B, it was tried to enhance the specific oxygenation activity in order to support their biotechnological applicability. The method of error prone PCR was used for that purpose. In order to identify favorable modifications with increased catalytic activity from a high number of mutants, an easy and simple screening test is necessary. Therefore, it is reasonable to use the ability of SMOs to oxidize indole to the blue dye indigo. However, the expression of SMOs as soluble proteins is an important requirement for any activity screening. Attempts to modify the genes styA2B and styA1/styA2B by means of a commercial error prone PCR kit yielded 300 to 1,200 potential mutants. Unfortunately, none of the obtained colonies showed any indole-oxidizing activity and the formation of insoluble inclusion bodies was assumed to be a likely explanation. In contrast to StyA2B and StyA1, recombinant expression of the artificial fused SMOs StyAL1B und StyAL2B should yield detectable amounts of active proteins. In fact, cultivation of clones expressing both types of proteins showed a blue coloration. Since the coloration of clones from one single solid medium evolved in a non-uniform manner, cultivation conditions were varied in order to identify factors which promote a more uniform tendency for indole oxidation. Although a high NaCl concentration in the medium was shown to favor indole oxidation, the latter one seems to be influenced by additional physiological factors, hardly to control. For the artificially fused proteins an error prone PCR was carried out, too. Although the initial step of mutagenic PCR was found to be successful, completing the vector system by a second ll-up PCR reaction failed. Alternative strategies like the usage of alternative DNA polymerases as well as a conventional cloning approach of various genes into a digested expression vector did not lead to detectable clones. The cultivation of identical clones on petri dishes provided no uniform tendency for indole oxidation and thus did not allow the reliable comparison of mutants in respect of their specific SMO activities. Cultivation of mutants in liquid medium should lead to more reproducible conditions and for that purpose a method was successfully established to quantify indigo formation and cell density.:Eidesstattliche Erklärung II Danksagung III Zusammenfassung IV Abstract VI Abbildungsverzeichnis XI Tabellenverzeichnis XIII Abkürzungsverzeichnis XIV 1 Einleitung 1 1.1 Styrol - ein Produkt der Industrie . . . . . . . . . . . . . . . . . . . . . . . 1 1.2 Styrol-Monooxygenasen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 1.2.1 Abbauwege von Styrol . . . . . . . . . . . . . . . . . . . . . . . . . 2 1.2.2 Struktur, Vorkommen und Eigenschaften klassischer Zweikomponenten Styrol-Monooxygenasen . . . . . . . . . . . . . . . . . . . . 4 1.2.3 Das neuartige Styrol-Monooxygenase-System StyA1/StyA2B aus Rhodococcus opacus 1CP . . . . . . . . . . . . . . . . . . . . . . . . 6 1.2.4 Künstlich verlinkte SMO aus Pseudomonas uorescens ST . . . . . 7 1.2.5 Biotechnologischer Einsatz von Styrol-Monooxygenasen . . . . . . . 8 1.3 Strategien des Protein-Engineering . . . . . . . . . . . . . . . . . . . . . . 9 1.3.1 Arbeitsmethoden zur Veränderung von DNA . . . . . . . . . . . . . 9 1.3.2 Error prone PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 1.4 Arbeitsziele . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 2 Material und Methoden 13 2.1 Bakterienstämme und Plasmide . . . . . . . . . . . . . . . . . . . . . . . . 13 2.2 Kultivierungsmedien und -bedingungen . . . . . . . . . . . . . . . . . . . . 14 2.2.1 Kultivierungsmedien . . . . . . . . . . . . . . . . . . . . . . . . . . 14 2.2.2 Kultivierungstemperaturen . . . . . . . . . . . . . . . . . . . . . . . 14 2.3 Polymerase-Kettenreaktion (PCR) . . . . . . . . . . . . . . . . . . . . . . 16 2.3.1 Primer und Primerdesign . . . . . . . . . . . . . . . . . . . . . . . . 16 2.3.2 Standard-PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 2.4 Fehlerbehaftete Polymerase-Kettenreaktion (epPCR) . . . . . . . . . . . . 17 2.4.1 Synthese der mutagenen Megaprimer . . . . . . . . . . . . . . . . . 18 2.4.2 EZClone Reaktion . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 2.4.3 Transformation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 2.4.4 Modi zierung des Protokolls des EZClone Reaktion Schrittes . . . . 20 2.5 Aufreinigung von PCR-Produkten aus der Lösung . . . . . . . . . . . . . . 20 2.6 TAE-Agarose-Gelelektrophorese . . . . . . . . . . . . . . . . . . . . . . . . 20 2.7 DNA-Extraktion aus Agarosegelen . . . . . . . . . . . . . . . . . . . . . . 21 2.8 Bestimmung der DNA-Konzentration . . . . . . . . . . . . . . . . . . . . . 21 2.9 Restriktionsverdau von DNA . . . . . . . . . . . . . . . . . . . . . . . . . . 21 2.10 Ligation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 2.11 Herstellung von kompetenten Zellen (E.coli DH5ff, E. coli BL21) . . . . . 23 2.11.1 Chemisch kompetente Zellen nach der CaCl2-Methode (42) . . . . . 23 2.11.2 TOP10 chemischkompetente Zellen . . . . . . . . . . . . . . . . . . 23 2.12 Transformation nach der Hitzeschock-Methode (19) . . . . . . . . . . . . . 24 2.13 Plasmidpräparation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 2.14 Bestimmung der Indigobildung durch Klone mit mutmaÿlicher SMO-Aktivität 24 2.14.1 Abschätzung der Indigobildung durch Augenschein . . . . . . . . . 25 2.14.2 Quanti zierung der Indigobildung mittels UV/Vis-Spektrophotometrie 25 2.14.3 Quanti zierung der Indigobildung aus Flüssigkulturen . . . . . . . . 26 3 Ergebnisse 27 3.1 Versuche der error prone PCR von StyA2B aus Rhodococcus opacus 1CP . 27 3.1.1 Isolation von Templat-DNA und Durchführung der error prone PCR 28 3.1.2 Screening von Transformanden auf Fähigkeit zur Indol-Oxidation . 29 3.1.3 Herstellung und Aktivitätsscreening von E. coli DH5ff pET_StyA2B 30 3.2 Versuche der error prone PCR von styA1/styA2B aus Rhodococcus opacus 1CP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 3.2.1 Durchführung der error prone PCR und Aktivitätsscreening von StyA1/StyA2B in pBluescript KS(+) . . . . . . . . . . . . . . . . . 31 3.2.2 Durchführung des Aktivitätsscreening von StyA1/StyA2B in pET16bP 32 3.3 Fusionsproteine StyAL1B und StyAL2B aus Pseudomonas uorescens ST . 33 3.3.1 Optimierung der Zusammensetzung des LB-Mediums für das Aktivitätsscreenings von pET_StyAL2B in E. coli BL21 nach einer Transformation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 3.3.2 Ein uss der Belüftung auf die Neigung von E. coli BL21 (pET_StyAL2B) Kolonien zur Oxidation von Indol . . . . . . . . . . . . . . . . . . . 38 3.3.3 Bestimmung der Indigobildung mittels UV/Vis-Spektroskopie . . . 40 3.3.4 Zeitliche Entwicklung der Indigokonzentration einer Flüssigkultur von E. coli BL21 (pET_StyAL2B) . . . . . . . . . . . . . . . . . . 42 3.3.5 Error prone PCR von pET_StyAL2B mit Gene Morph II EZ Clone Kit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 3.3.6 Error prone PCR nach der klassischen Methode mit pET_StyAL1B und pET_StyAL2B . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 4 Diskussion der Ergebnisse 49 4.1 Die error prone PCR als attraktive Methodik zur Optimierung von Styrol- Monooxygenasen hinsichtlich katalytischer Eigenschaften . . . . . . . . . . 49 4.2 Der Aktivitätsnachweis als mutmaÿlich limitierender Schritt in der Modi- zierung von StyA2B und StyA1/StyA2B mit Hilfe der error prone PCR . 51 4.3 Die künstlich fusionierten Styrol-Monooxygenasen StyAL2B und StyAL1B erlauben ein Aktivitätsscreening auf Platte . . . . . . . . . . . . . . . . . . 53 4.4 Die Entwicklung einer Methodik zur Quanti zierung der spezi schen Indigobildung eines Expressionsklons der Styrol-Monooxygenase StyAL2B . . . 58 4.5 Fehleranalyse zur error prone PCR . . . . . . . . . . . . . . . . . . . . . . 59 4.5.1 Fehler in der klassischen error prone PCR für pET_StyAL1B und pET_StyAL2B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 Literaturverzeichnis 65